Navigation Links
Revolutionary Healing Technology for Treating Difficult and Chronic Wounds Approved by Health Canada

TORONTO, June 6 /PRNewswire/ - Archimed, the woundcare division of Insense Ltd., today announced it has received approval from Health Canada for the use of its revolutionary Oxyzyme product in the treatment of difficult and chronic wounds. Oxyzyme was first trialed in Toronto by Dr. Gary Sibbald, one of the world's leading wound care specialists, in 2004 by his team at the Toronto Wound Healing Centres. The announcement was made at the 3rd Congress of the World Union of Wound Healing Societies taking place from June 4-8, 2008 at the Metro Toronto Convention Center.

Oxyzyme is a biochemical system in a dressing that ensures the oxygen in the wound environment meets the diverse oxygen needs of the cells responsible for healing. Ongoing clinical programs being undertaken in Europe are showing that 20% of old, previously unhealable wounds (3.5 years) are now closing in six weeks or under when dressed with Oxyzyme. Easy to use by any clinical professional, Oxyzyme will now soon be available to the Canadian health care system at a modest cost.

In conjunction with the announcement, Professor T.K. Hunt, often cited as the father of modern wound care, was awarded a lifetime achievement award by the World Union of Wound Healing Societies. Professor Hunt's insight and discoveries on the role oxygen plays in the healing process was the inspiration behind the development of Oxyzyme.

"The real value of Oxyzyme is that it combines two agents - iodine and oxygen - that are essential to the process of wound healing and provides further opportunities to overcome barriers to healing that may exist in the patient," explained Dr. Keith Harding, leading figure in the international wound care community and also a member of the World Union faculty.
For more information about Oxyzyme and Archimed visit

About Insense Ltd.

------------------ Insense is a British biotechnology company founded by Professor Paul Davis, Chief Scientific Officer, who led the team which invented and developed the ClearBlue(TM) pregnancy test. The company is also developing products out of its core technology for dermatology and health and beauty applications. For more information about Insense Ltd. visit

SOURCE Insense Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ORF Genetics Opens Revolutionary Green Factory in Iceland
2. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
3. SimBioSys Utilizes Revolutionary Hardware Technology to Open New Frontiers in Molecular Modeling
4. NASA MidSTAR-1 successful technologies may be revolutionary
5. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
6. Webcam MD - Launch of revolutionary web-based medical technology
7. FDA Clears Biospace meds Revolutionary Low Dose Xray Imager
8. Cooler Solutions and Leading Research Hospital to Design Revolutionary Osteoporosis Diagnosis Device
9. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. Advanced BioHealing and Regenesis Biomedical Form Co-Promotion Alliance for Dermagraft(R)
Post Your Comments:
(Date:11/30/2015)... NORTH CHICAGO, Ill. , Nov. 30, 2015 /PRNewswire/ ... an all-inclusive program that focuses on a daily routine ... how patients take their medication can affect the way ... establish and follow to their a daily routine are ... is to help patients better manage their hypothyroidism ...
(Date:11/30/2015)... TIKVAH, Israel , Nov. 30, 2015 /PRNewswire/ ... a leading developer of adult stem cell technologies for neurodegenerative ... Ltd., has been awarded an additional grant of approximately $735,000 ... Scientist (OCS). This grant, the second this year, brings the ... approximately $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... India , November 27, 2015 /PRNewswire/ ... --> Growing popularity of companion diagnostics ... in cancer biomarkers market with pharmaceutical companies ... in-demand companion diagnostic tests. ... --> Complete report on global cancer ...
(Date:11/25/2015)... ANNAPOLIS, Md. , Nov. 25, 2015  PharmAthene, ... of Directors has adopted a stockholder rights plan (Rights ... its net operating loss carryforwards (NOLs) under Section 382 ... --> --> PharmAthene,s use of its ... an "ownership change" as defined in Section 382 of ...
Breaking Biology Technology:
(Date:11/20/2015)... 20, 2015 NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... , was recently interviewed on The RedChip Money ... this weekend on Bloomberg Europe , Bloomberg Asia, ... --> NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:11/18/2015)... York , November 18, 2015 ... Research has published a new market report titled  Gesture ... Trends, and Forecast, 2015 - 2021. According to the report, ... 2014 and is anticipated to reach US$29.1 bn by ... 2021. North America dominated ...
(Date:11/17/2015)... EASTON, Mass. , Nov. 17, 2015 ... a leader in the development and sale of broadly ... the worldwide life sciences industry, today announced it has ... of its $5 million Private Placement (the "Offering"), increasing ... to $4,025,000.  One or more additional closings are expected ...
Breaking Biology News(10 mins):